The Grünenthal Group
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.
Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. These investments amounted to about 26 percent of revenues in 2012.
Contract with chairman of Grünental Group’s Corporate Executive Board extended
The Grünenthal Group today announced that the advisory board of the international pharmaceutical company prolonged the contract with the chairman of its Corporate Executive Board, Professor Dr. Eric-Paul Pâques, ahead of time and confirmed him in office as Chief Executive Officer for another three years.